Association study of ABCB1 and CYP3A5 gene polymorphisms with sirolimus trough concentration and dose requirements in Chinese renal transplant recipients

被引:64
作者
Miao, Li-Yan [1 ]
Huang, Chen-Rong [1 ]
Hou, Jian-Quan
Qian, Mei-Ying [1 ]
机构
[1] Soochow Univ, Affiliated Hosp 1, Clin Pharmacol Res Lab, Suzhou 215006, Peoples R China
关键词
sirolimus; gene polymorphism; ABCB1; CYP3A5; renal transplant recipients;
D O I
10.1002/bdd.577
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The objective of this study was to investigate the possible association of the ABCB1 gene C3435T polymorphism and the CYP3A5 gene A6986G polymorphism with sirolimus (SRL) trough concentration and dose requirements in Chinese stable renal transplant recipients. Blood samples were collected from 105 healthy volunteers and 50 renal transplant patients, whose polymorphisms of the ABCB1 and CYP3A5 genes were determined by polymerase chain reaction (PCR)-restriction fragment length polymorphism (RFLP). Plasma concentrations of SRL were determined with HPLC. The allele frequencies of the ABCB1 mutation in Chinese healthy volunteers and renal transplant recipients were 51.0% and 44.0% (p>0.05), while the allele frequencies of the CYP3A5 mutation were 72.9% and 71.0% (p>0.05). The SRL concentration/dose ratio (C/D) in patients with CYP3A5 *3/*3 were significantly higher than that of those with *1 allele (p<0.05). However, no significant differences were observed between C/D and ABCB1 SNPs (p>0.05). These results confirm that when treated with a SRL-based therapy and low-dose steroids, patients carrying the CYP3A5*1 allele required significantly more SRL to achieve adequate blood trough concentrations. In patients with SRL-based therapy, genotyping of the CYP3A5 genes may help to optimize the SRL management in renal transplant recipients. Copyright (C) 2007 John Wiley & Sons, Ltd.
引用
收藏
页码:1 / 5
页数:5
相关论文
共 16 条
[1]   Consequences of genetic polymorphisms for sirolimus requirements after renal transplant in patients on primary sirolimus therapy [J].
Anglicheau, D ;
Le Corre, D ;
Lechaton, S ;
Laurent-Puig, P ;
Kreis, H ;
Beaune, P ;
Legendre, C ;
Thervet, E .
AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 (03) :595-603
[2]   Hyperlipidemia in renal transplant recipients treated with sirolimus (rapamycin) [J].
Brattström, C ;
Wilczek, H ;
Tydén, G ;
Böttiger, Y ;
Säwe, J ;
Groth, CG .
TRANSPLANTATION, 1998, 65 (09) :1272-1274
[3]   In vitro and in situ absorption of SDZ-RAD using a human intestinal cell line (Caco-2) and a single pass perfusion model in rats:: Comparison with rapamycin [J].
Crowe, A ;
Lemaire, M .
PHARMACEUTICAL RESEARCH, 1998, 15 (11) :1666-1672
[4]   Sirolimus-induced thrombocytopenia and leukopenia in renal transplant recipients: Risk factors, incidence, progression, and management [J].
Hong, JC ;
Kahan, BD .
TRANSPLANTATION, 2000, 69 (10) :2085-2090
[5]   The genetic determinants of the CYP3A5 polymorphism [J].
Hustert, E ;
Haberl, M ;
Burk, O ;
Wolbold, R ;
He, YQ ;
Klein, K ;
Nuessler, AC ;
Neuhaus, P ;
Klattig, J ;
Eiselt, R ;
Koch, I ;
Zibat, A ;
Brockmöller, J ;
Halpert, JR ;
Zanger, UM ;
Wojnowski, L .
PHARMACOGENETICS, 2001, 11 (09) :773-779
[6]   Therapeutic drug monitoring of sirolimus: correlations with efficacy and toxicity [J].
Kahan, BD ;
Napoli, KL ;
Kelly, PA ;
Podbielski, J ;
Hussein, I ;
Urbauer, DL ;
Katz, SH ;
Van Buren, CT .
CLINICAL TRANSPLANTATION, 2000, 14 (02) :97-109
[7]   Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression [J].
Kuehl, P ;
Zhang, J ;
Lin, Y ;
Lamba, J ;
Assem, M ;
Schuetz, J ;
Watkins, PB ;
Daly, A ;
Wrighton, SA ;
Hall, SD ;
Maurel, P ;
Relling, M ;
Brimer, C ;
Yasuda, K ;
Venkataramanan, R ;
Strom, S ;
Thummel, K ;
Boguski, MS ;
Schuetz, E .
NATURE GENETICS, 2001, 27 (04) :383-391
[8]  
Lampen A, 1998, J PHARMACOL EXP THER, V285, P1104
[9]   CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients [J].
Le Meur, Yannick ;
Djebli, Nassim ;
Szelag, Jean-Christophe ;
Hoizey, Guillaume ;
Toupance, Olivier ;
Rerolle, Jean Philippe ;
Marquet, Pierre .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 80 (01) :51-60
[10]   Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine [J].
Lown, KS ;
Mayo, RR ;
Leichtman, AB ;
Hsiao, HL ;
Turgeon, DK ;
SchmiedlinRen, P ;
Brown, MB ;
Guo, WS ;
Rossi, SJ ;
Benet, LZ ;
Watkins, PB .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1997, 62 (03) :248-260